KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. - Wikidata - awgldk - TriplyDB

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.

http://www.wikidata.org/entity/Q33428782

about

Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life Endometriosis and ovarian cancer: links, risks, and challenges faced The molecular background of mucinous carcinoma beyond MUC2 The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples.An integrative approach to identifying cancer chemoresistance-associated pathways Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects.Discovery of prognostic factors for diagnosis and treatment of epithelial-derived ovarian cancer from laying hens.REDD1 and p-AKT over-expression may predict poor prognosis in ovarian cancer Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer.Overexpression of the β subunit of human chorionic gonadotropin promotes the transformation of human ovarian epithelial cells and ovarian tumorigenesis.Biochip-based detection of KRAS mutation in non-small cell lung cancer.Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug.Identification of multiple pathways involved in the malignant transformation of endometriosis (Review)Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones.Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria.Ovarian cancer in endometriosis: clinical and molecular aspects.Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.New and potential clinical applications of KRAS as a cancer biomarker.Oncogenes associated with drug resistance in ovarian cancer.KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues A case of synchronous pancreatic ductal adenocarcinoma and ovarian mucinous cystic neoplasm: use of kras mutation molecular phenotyping to demonstrate independent primary origin.The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma.Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors.Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas.HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.

P2860

Q26777453-27E0073A-24F3-43CF-94A4-F9F2F0114052 Q26785614-53570C25-173D-4183-B771-2E1E11819FA1 Q27003273-2B5B0BE1-C487-40B5-A6EF-2E0E5CA68C08 Q28083904-5D2B3889-333F-46C8-99BB-38D1535504BD Q28744228-79635643-FA53-4AB0-8AD6-34357F5061B0 Q33739695-25D39697-6B83-4685-A5E4-795729A3B36D Q33768759-7E25A23F-6A3F-454A-A882-AF11AB829CBD Q33853380-63A69C54-F357-4A50-B409-2178B62A2E47 Q34033619-B8D49055-0C58-417C-A827-45CD484FED50 Q34305434-0C88AF92-1C00-4190-AA3F-9A6ACA7765D8 Q34371477-5EAFB65F-CF12-482B-802F-7AE9764C6EF6 Q34586019-A180C437-E38D-4950-B5DA-5C6A5D8D160A Q34887528-D45BB518-1F12-4652-90DC-21C1052B0655 Q35168182-432C70F4-0994-46D3-9F00-D5A8BA0F4805 Q35669440-45FAEB4E-9AF0-4953-B6FC-65BCEA32D85C Q36092073-7F5F6DBE-64BB-4A1C-898B-7C68ACCDA058 Q36099250-FD815F42-AE88-450A-BE57-5062ABBC904F Q36917897-82D176A9-3991-40F8-9C87-89522F08B7F5 Q37042308-04051256-5ED3-4D63-9509-DA3F61F9F0F7 Q37420213-37CE946B-F634-4A9B-96CE-03BC64F6030C Q37485865-2A49F373-0645-4D90-82F1-E4CEBD95E3C4 Q37632101-617BE80F-2F34-4FB9-A300-B413025AF419 Q37645709-F9F306D8-98A1-4964-8EC9-6419885420A7 Q37696086-CE2E0D45-34A5-4C48-A2DA-705E6A3FFE74 Q38089885-68B2E120-DA5F-4459-80EF-BE83B0BE1A86 Q38226577-E0E17226-C084-4A1D-AA83-2E0AE0C9BAF2 Q38409695-7C40142E-481B-4CA6-812E-6EA7F2A7B0B9 Q42186610-975F5EB3-435A-4287-A426-33E1EB1C2761 Q42339944-44CF473C-CEA3-4B2F-BAAA-7DB6BBF350D3 Q46879650-A38BC00E-B193-4CC9-8F01-D947C6867E4C Q49937490-5E862916-7B74-46AB-A033-EF62ED69C847 Q50742113-E4F70624-8D93-48E9-8E86-25F16B3BFAC2 Q52808198-D95212CE-660C-41E5-AE5D-A08F20005FC2

P2860

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.

http://www.wikidata.org/entity/Q33428782

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.

@ast

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.

@en

type

label

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.

@ast

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.

@en

prefLabel

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.

@ast

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.

@en

P1433

Q33428782-8DA6EDE8-1452-4F18-A6E1-7FBC4FBC3C25

P1476

Q33428782-A89FCB44-2059-49E6-AE7A-1EABFABF7DEA

P2093

Q33428782-0F949BE1-7ED9-445E-B493-7290CC02CCFC

Q33428782-4DAC40AA-31AA-403D-9CC5-C8DBF5F6462C

Q33428782-7A7C2026-8A01-4FD5-A493-990EE84AA646

Q33428782-7FB48C62-7CC9-4825-8325-F09E5A9062FE

Q33428782-D8F1F48A-A467-41E8-8FE0-1A67B56D04D8

Q33428782-D9EE1A23-A1D8-4194-8D82-ABBA32256ADA

P2860

Q33428782-06F1CCF1-33F4-4212-BB2B-B4C2FAD4EAF7

Q33428782-199AE0BB-BC51-4BDF-B75B-3578F99AF878

Q33428782-3D1A694E-2729-4CE3-A6E8-AD8F1EFF9771

Q33428782-417A9E7F-BC22-4BAF-9644-4E98454A7966

Q33428782-44E59EB0-26E4-4F93-B344-D6D396F73D09

Q33428782-4F007804-7D44-49E2-99E7-CA1DE509065B

Q33428782-600D2DE2-0A51-4DF3-B4C6-1E200C9BBCB7

Q33428782-67F7F0C9-E0A5-48CD-A604-9235B7822752

Q33428782-71416092-F811-45BB-82E8-45FA5E71C492

Q33428782-797F87B9-10EB-4C3E-9EC2-DD851F16DD59

P2888

Q33428782-B4083E11-C443-4D5A-9B54-4184D3D068F7

P304

Q33428782-E1968C89-49F1-4C65-BEFE-546724A14390

P31

Q33428782-691B2239-AED3-4499-9FEA-B89817A6B90C

P356

Q33428782-8678C91E-5B52-49C0-B32C-FA49C6A52A31

P407

Q33428782-6B002FC4-6F64-4D57-8064-FFA28F547286

P478

Q33428782-2262ADB4-D7F9-4FD9-815F-3A4CE0CE72E7

P50

Q33428782-8A9B438A-9C6C-4C41-8ADE-F2CD9CD2917B

P577

Q33428782-5C39CAA2-862E-4907-B6FC-6097110082B4

P5875

Q33428782-62A44C72-6A88-49CA-812B-40EA0BC93D1E

P6179

Q33428782-1FF2AA95-272F-4C86-96ED-C97E84544587

P698

Q33428782-3A80A4C3-2676-4E95-9101-CFCD7D10DC95

P932

Q33428782-9276DCFE-CB97-4F2F-B276-C7404B0DC66C

P356

1471-2407-9-111

P1433

P1476

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.

@en

P2093

Alexander Mustea

http://www.w3.org/2001/XMLSchema#string

Alexander Reinthaller

http://www.w3.org/2001/XMLSchema#string

Dan Tong

http://www.w3.org/2001/XMLSchema#string

Gernot Kriegshäuser

http://www.w3.org/2001/XMLSchema#string

Reinhard Horvat

http://www.w3.org/2001/XMLSchema#string

Veronika Auner

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

ras oncogenes in human cancer: a review

Diagnostic biochip array for fast and sensitive detection of K-ras mutations in stool.

K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy.

Genetic alterations in ovarian borderline tumours and ovarian carcinomas.

Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes.

Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.

K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary

The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer.

P2888

1471-2407-9-111

P304

111

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-9-111

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Robert Zeillinger

P577

2009-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24270334

http://www.w3.org/2001/XMLSchema#string

P6179

1002772136

http://www.w3.org/2001/XMLSchema#string

P698

19358724

http://www.w3.org/2001/XMLSchema#string

P932

2671522

http://www.w3.org/2001/XMLSchema#string